Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors by Elizabeth S. Yeh et al.
PRECLINICAL STUDY
Regulation of cell survival by HUNK mediates breast cancer
resistance to HER2 inhibitors
Elizabeth S. Yeh • Melissa A. Abt • Elizabeth G. Hill
Received: 17 June 2014 / Accepted: 1 December 2014 / Published online: 17 December 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Breast cancer patients who are HER2-positive
receive targeted inhibitors to HER2, including trastuzumab
and lapatinib. While patients benefit from the use of HER2
inhibitors, many fail therapy and almost all patients
become resistant to treatment, indicating a critical need to
prevent treatment failure. Several recent studies indicate
that activation of autophagy contributes to trastuzumab and
lapatinib resistance and demonstrate that impairing
autophagy in breast cancer cells is therapeutically benefi-
cial. Moreover, autophagy is mechanistically linked
through signaling crosstalk to apoptotic pathways, where
activation of one process impacts the other. Therefore,
understanding the molecular mechanisms that control these
processes may uncover novel areas of therapeutic inter-
vention to combat or prevent resistance in breast cancer.
We previously characterized the protein kinase HUNK as a
breast cancer-promoting factor in HER2/neu-induced
mammary tumor models, in which HUNK supported the
survival of HER2/neu-positive tumor cells, likely through
the regulation of apoptosis. Because significant crosstalk
exists between apoptotic and autophagy proteins, we now
examine if HUNK is also able to regulate cell survival
through modulation of autophagy using HER2 inhibitor
sensitive and resistant breast cancer models. Furthermore,
we investigate whether inhibiting HUNK impairs in vivo
tumor growth that is initiated by HER2 inhibitor-resistant
breast cancer cells. Our findings indicate that therapeuti-
cally targeting HUNK is a potential strategy for over-
coming resistance and that resistant breast cancer cells
maintain HUNK expression to drive tumorigenesis, an
observation that is consistent with a pro-survival role for
this kinase.
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Introduction
Hormonally Upregulated Neu-associated kinase is a
member of the AMPK-family of protein kinases that was
discovered in a RT-PCR-based screen to identify kinases
expressed in the adult mammary gland [1]. Previous find-
ings indicate that HUNK is preferentially expressed in
aggressive subsets of breast cancer and may play a pivotal
role in mediating breast cancer metastasis [2, 3]. Consistent
with these assertions, our previous work shows that HUNK
expression is regulated in response to HER2/neu activity
and inhibiting this kinase impairs tumor formation and
growth in primary HER2/neu tumor models [4].
Although little is known about the intracellular function
of HUNK, evidence is mounting that this kinase partici-
pates in the regulation of cell survival. Studies demonstrate
that impairing HUNK in HER2/neu-positive (HER2?) and
Akt-dependent mammary tumor models induces cell death
by apoptosis [4, 5]. Moreover, studies using Hunk-/-
(Hunk KO) mice show that normal mammary gland
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development is altered by loss of HUNK function during
postlactational involution, a stage of mammary gland
development governed by apoptotic clearance of mammary
epithelial cells, where Hunk KO mice display increased
levels of apoptosis during involution [5].
The process of autophagy has been linked to apoptosis
[6], and we have previously shown that HUNK mediates
apoptosis [4, 5]. However, a role for HUNK in autophagy
has not been investigated. Because significant crosstalk
exists between signaling pathways that regulate apoptosis
and autophagy, in this study, we aimed to demonstrate that
HUNK regulates autophagy in a manner consistent with its
ability to regulate cell survival and show that the outcome




All cells were maintained at 37 C and 5 % CO2. Hunk?/?
(Hunk WT)and Hunk-/-(Hunk KO) mammary gland
fibroblasts (MGF) were isolated as previously described [5]
and were grown in DMEM (Hyclone) supplemented with
10 % super calf serum (SCS, Gemini). BT474 (ATCC)
human breast cancer cells were grown in RPMI-1640
(Hyclone) supplemented with 10 % fetal bovine serum
(FBS, Gibco). BT474 cells expressing control or HUNK
shRNA (gift from Lewis Chodosh, University of Pennsyl-
vania) were generated and maintained as previously
described [4]. JIMT-1 (Addex Bio) trastuzumab-resistant
breast cancer cells were grown in DMEM (Hyclone) sup-
plemented with 10 % FBS. JIMT-1 cells expressing control
or HUNK shRNA were generated using the pGIPZ system
(Thermo-GE/Dharmacon) and maintained in media con-
taining 1 ug/ml puromycin. All media contained 2 mM
glutamine (Thermo Scientific) and Penicillin/Streptomycin
(Pen/Strep, Thermo Scientific) unless otherwise specified.
pEGFP-LC3 was acquired through Addgene (plasmid
#24920, provided by TorenFinkel [7] ). Transfection of
GFP-LC3 was performed using Turbofect (Thermo
Scientific).
Immunoblotting
Cells were lysed in buffer containing final concentrations
of 50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 % Triton
X-100; and 0.1 % SDS supplemented with HALT protease
and phosphatase inhibitor cocktail (Thermo Scientific). For
near-infrared imaging (Odyssey, LI-COR), secondary
antibodies were purchased from Rockland Scientific. Pri-
mary antibodies used for western blotting are anti-LC3B
(Cell Signaling- 2775), anti-HUNK [4], and anti-b-tubulin
(Santa Cruz).
RNA isolation and quantitative Real-Time PCR
RNA was prepared using the GeneJet RNA isolation kit
(Thermo Scientific). Reverse transcription was performed
using the Maxima First Strand cDNA Synthesis Kit for RT-
PCR (Thermo Scientific). The resulting cDNA was used to
perform quantitative Real-Time PCR (QRT-PCR) using the





Equal numbers of cells were plated and treated the fol-
lowing day by serum deprivation for 24 h or with 100 nM
lapatinib (Santa Cruz) for 24 h prior to analysis by Cas-
pase-3 activity assay (Sigma) or trypan blue exclusion and
cell counting, which was performed using the cellometer
mini cell counter (Nexcelom). For autophagy, cells were
treated with 100 uM chloroquine (Sigma) for the indicated
times and analyzed by Western blotting or microscopy
(Nikon E800).
In vivo tumorigenesis
Animal care and all animal experiments were performed
with the approval and in accordance with the guidelines of
the Medical University of South Carolina IACUC. For
orthotopic tumor analysis, 5 9 106 cells were injected in
the abdominal mammary fat pat of immunocompromised
mice (Nu/J-Foxn1nu/nu, Jackson Labs). Tumors were eval-
uated by manual palpation using calipers.
Statistical considerations for animal data
Tumor volume data from mouse experiments were ana-
lyzed using generalized estimating equations (GEEs) [8, 9]
with an identity link function and exchangeable correlation
structure, a regression model that accommodates the lack
of independence among measures obtained from the same
mouse over time. Specifically, we modeled volume (mm3)
as a function of animal group (control versus HUNK
shRNA), days from cell injection (measured as a continu-
ous variable), and their two-way interaction. We used
restricted cubic splines [10] to transform days from cell
injection due to observed non-linear trends in tumor vol-
ume over time. Comparisons between groups at each time
point were performed using model-based linear contrasts.
We used Kaplan–Meier survival curves to estimate group-
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specific median time to sacrifice, and compared survival
times using a log-rank test. We used a similar approach to
compare time to tumor volume of 100 mm3. Analyses of
animal data were performed using the R statistical software
package [11]. GEEs were fit using the geepack library in R
[12]. Kaplan–Meier curves and log-rank tests were con-
ducted using the survival library in R [13].
Results
Autophagy is impaired in Hunk-deficient cells
We previously demonstrated that HUNK regulates cell
survival [4, 5]. Our findings indicated that impairing
HUNK in mammary epithelial, mammary tumor, and
breast cancer cells results in an increase in the number of
cleaved-caspase-3 positive cells in mammary gland and
tumor models [4, 5], suggesting that inhibiting this kinase
results in cell death via apoptosis. To further investigate the
role of HUNK in cell survival, we examined MGF isolated
from Hunk WT and Hunk KO mice for survival response.
Equal numbers of Hunk WT and Hunk KO MGF were
plated and then assessed by trypan blue exclusion. Con-
sistent with our previous findings that HUNK-deficient
cells are survival impaired, Hunk KO MGF exhibited
decreased numbers of viable cells after plating (Fig. 1a).
Because the signaling pathways that govern apoptosis
affect a cell’s ability to undergo autophagy [6], we wanted
to ask if loss of HUNK alters autophagy. To evaluate
autophagy response, we performed Western bot analysis
for LC3B processing from LCBI to LCBII to detect levels
of LC3BII formation. Equal numbers of Hunk WT and
Hunk KO cells were plated and the following day treated
with vehicle (water) or the autophagy inhibitor, chloro-
quine for 4 h. We used chloroquine because it is an
autophagy inhibitor that impairs autophagic flux. Conse-
quently, chloroquine treatment results in an accumulation
of autophagosomes which incorporate LC3BII, if autoph-
agy is proceeding as expected. Following chloroquine
treatment of the Hunk WT and Hunk KO cells, we assessed
for LC3BII levels by immunoblotting using the Odyssey
imaging system. We found that chloroquine-treated Hunk
KO cells did not accumulate LC3BII when compared to
Hunk WT cells, which had increased LC3BII levels in
response to chloroquine treatment (Fig. 1b), suggesting
that in Hunk KO cells basal autophagy is likely impaired.
We confirmed these results by monitoring autophagy by
GFP-LC3 to quantitate accumulation of GFP-puncta. Equal
numbers of Hunk WT and Hunk KO cells were transfected
with GFP-LC3 and treated with chloroquine the following
day for 4 h. Cells were then evaluated by immunofluores-
cence (IF) for the average number of GFP-positive puncta
per cell. We found that Hunk KO cells exhibited a reduced
number of GFP-LC3 puncta per cell under chloroquine
treatment conditions (Fig. 1c-IF, Fig. 1d-quantitation)
indicating that loss or impairment of HUNK alters
autophagy response. Moreover, these results are consistent
with our immunoblotting results and suggest that in the
absence of HUNK, autophagy is impaired.
HUNK down-regulation in primary HER2-positive
breast cancer cells induces cell death in response
to lapatinib and alters autophagy response
Because we previously demonstrated that HUNK is
upregulated by HER2/neu and acts as a tumor-promoting
factor in HER2? breast cancer [4], we next sought to
examine cell death and autophagy response in HER2?
breast cancer cells. Therefore, we used BT474 cells engi-
neered to express control shRNA or shRNA targeted to
HUNK (Fig. 2a) and examined the cells for survival
response. Consistent with what we previously reported [4],
HUNK shRNA-expressing BT474 cells had increased
Fig. 1 HUNK promotes cell survival and regulates autophagy
a Equal numbers of Hunk WT and Hunk KO MGF were plated in
quadruplicate into normal media and counted 24 h later. *p \ 0.001
(Student’s t test). b Equal numbers of Hunk WT and Hunk KO MGF
were plated and the following day treated with vehicle (water) or
100 uM chloroquine for 4 h. Resulting lysates were then immuno-
blotted for LC3BI and LC3BII levels using anti-LC3 Bantibody
c Equal numbers of Hunk WT and Hunk KO MGF were seeded onto
glass coverslips in triplicate and transfected with pcDNA-GFP-LC3.
The following day, cells were treated with vehicle (water) or 100 uM
chloroquine for 4 h, fixed, and stained with DAPI. d GFP-LC3
positive puncta were quantitated and averaged in at least 3 fields per
slide, for 3 separate experiments. *p \ 0.01 (Student’s t test)
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levels of caspase-3 activity in response to serum with-
drawal (Fig. 2b), confirming that HUNK promotes cell
survival. To determine if HUNK mediates cell death in
response to HER2 inhibition, we treated control and
HUNK shRNA-expressing BT474 cells with lapatinib and
measured caspase-3 activity. We found that indeed, HUNK
shRNA-expressing BT474 cells were more sensitive to
lapatinib, resulting in higher levels of caspase-3 activity
(Fig. 2b).
We next evaluated levels of basal autophagy in control
and HUNK shRNA-expressing BT474 cells. Equal num-
bers of each cell type were plated and the following day
treated with chloroquine for 4 h. Following, cells were
assessed for levels of LC3BI processing to LC3BII.
Similar to our findings in Fig. 1b, we saw an increase in
LC3BII in control cells treated with chloroquine but this
did not occur in HUNK shRNA-expressing BT474 cells
(Fig. 2c).
Previously, it was determined that HER2? breast cancer
cells respond to HER2 inhibition by inducing autophagy as
a mechanism to survive inhibitor treatment [14–17].
Therefore, we next examined levels of LC3BI processing
to LC3BII in control and HUNK shRNA-expressing
BT474 cells that had been treated with lapatinib. Similar to
previously published results [16], we saw an increase in
LC3BII levels in control cells treated with lapatinib
(Fig. 2d, compare lane 1 to lane 2) but this increase in
LC3BII levels was not induced in HUNK shRNA BT474
cells treated with lapatinib (Fig. 2d, compare lane 3 to lane
4). To further evaluate the observed lack of LC3BII pro-
cessing, and thus possible diminished autophagy response
to lapatinib in HUNK shRNA cells, we additionally co-
treated HUNK shRNA cells with chloroquine and lapatinib
to assess LC3BII levels. Consistent with our observations
thus far, chloroquine treatment did not result in an accu-
mulation of LC3BII in HUNK shRNA cells also treated
with lapatinib (Fig. 2d, compare lane 4 to lane 5). More-
over, there was no difference in LC3BII levels between
HUNK shRNA cells treated with vehicle, lapatinib alone,
and those cell that had been treated with both lapatinib and
chloroquine (Fig. 2d, compare lanes 3, 4, and 5), implying
that autophagy is impaired due to HUNK deficiency in
BT474 HER2? breast cancer cells.
HUNK regulates cell survival in breast cancer cells
resistant to HER2-targeted therapy
As autophagy is induced by HER2? breast cancer cells in
response to HER2 inhibition as a means to promote sur-
vival, it has been suggested that autophagy is a mechanism
for developing resistance to HER2 inhibitors [14–17].
Therefore, we next wanted to ask if targeting HUNK in
cells that are resistant to HER2 inhibitor also alters cell
survival response. Therefore, we examined the JIMT-1
breast cancer cell line [18] for autophagy response by
LC3B processing. JIMT-1 cells were isolated from a
trastuzumab resistant patient and are insensitive to HER2
and EGFR inhibitors including lapatinib [18, 19].
We engineered JIMT-1 cells to express control or
HUNK shRNA (Fig. 3a).To evaluate autophagy, equal
numbers of control and HUNK shRNA-expressing JIMT-1
cells were plated and treated the following day with chlo-
roquine for 4 h. Following, samples were evaluated for
LC3BII levels by Western blotting. In agreement with our
findings in Fig. 1, HUNK shRNA-expressing JIMT-1 cells
also had impaired LC3BII processing in the presence of
chloroquine, whereas control cells accumulated LC3BII
under the same treatment conditions (Fig. 3b). We then
evaluated these cells for viability. Similar to our findings in
Fig. 1, we found that HUNK shRNA-expressing JIMT-1
cells had reduced viability (Fig. 3c) and increased cell
Fig. 2 HUNK knockdown in BT474 cells sensitizes cells to apop-
tosis and impairs autophagy a Quantitative Real-Time PCR (QRT-
PCR) analysis of HUNK expression levels in BT474 cells engineered
to express non-functional control shRNA or shRNA targeted to
HUNK. b Equal numbers of control and HUNK shRNA-expressing
BT474 were plated and either maintained in normal serum, washed in
PBS, and fed with no serum containing media, or treated with 100 nM
lapatinib. 24 h later, cells were analyzed for caspase-3 activity.
Experiments performed in quadruplicate. *p \ 0.01 (Student’s t test).
(c) Equal numbers of control and HUNK shRNA-expressing BT474
were plated. The following day, cells were treated with vehicle
(water) or 100 uM chloroquine for 4 h and analyzed by immuno-
blotting for LC3BI and LC3BII. d Equal numbers of control and
HUNK shRNA-expressing BT474 were plated. The following day
cells were treated with vehicle (DMSO) or 100 nM lapatinib for 24 h.
Cells treated with lapatinib plus chloroquine received 100 uM
chloroquine for 4 h prior to lysis. Lysates were analyzed by
immunoblotting for LC3BI and LC3BII. Quantitation is LC3BII/b-
tubulin
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death (Fig. 3d) in response to serum withdrawal when
compared to control JIMT-1 cells. Taken together, our data
suggest that targeting HUNK in HER2? primary and
resistant breast cancer cells induces cell death and impacts
the ability of these cells to undergo autophagy.
Targeting HUNK impairs tumor initiation and growth
in vivo of breast cancer cells resistant to HER2-targeted
therapy
To determine if the effect of targeting HUNK on cell death
and autophagy has an effect on tumorigenesis of breast
cancer cells resistant to HER2-targeted therapy, we next
assessed tumorigenesis in vivo. Equal numbers of control
or HUNK shRNA-expressing JIMT-1 cells were introduced
into the abdominal mammary gland of immunocompro-
mised mice and monitored for tumor formation and growth
over time. As predicted by the in vitro findings we report
here, targeting HUNK in JIMT-1 cells impaired tumor
growth (Fig. 4a), where the average tumor volume in the
HUNK shRNA group was significantly reduced from day
24 after injection onward (summarized in Table 1).
Furthermore, impairing HUNK in the resistant cells
improved overall survival time. Kaplan–Meier survival
curve estimate of median time to sacrifice was significantly
Fig. 3 HUNK knockdown in trastuzumab-resistant JIMT-1 cells
impairs autophagy and impacts survival. a Quantitative Real-Time
PCR (qRT-PCR) analysis of HUNK expression levels in JIMT-1 cells
engineered to express non-functional control shRNA or shRNA
targeted to HUNK. b Equal numbers of control and HUNK shRNA-
expressing JIMT-1 cells were plated. The following day, cells were
treated with vehicle (water) or 100 uM chloroquine for 4 h and
analyzed by immunoblotting for LC3BI and LC3BII. Quantitation is
LC3BII/b-tubulin. c Equal numbers of JIMT-1 control and HUNK
shRNA-expressing cells were plated in quadruplicate into normal
media. 18 h after plating, cells were washed in PBS and fed with
normal- or no-serum-containing media. Cells were subsequently
counted 24 h later and represented as the percent of cells that were
trypan blue negative.p values as indicated. (Student’s t test). d Quan-
titation of percent of dead cells from (c). p \ 0.001(Student’s t test)
Fig. 4 HUNK knockdown in trastuzumab-resistant JIMT-1 cells
impairs mammary tumorigenesis in vivo. a 5 9 106 control or HUNK
shRNA-expressing JIMT-1 cells were injected into the abdominal
mammary fat pad of immunocompromised nude mice and monitored
for tumor volume over time. Average tumor volume and correspond-
ing standard errors at each time point, n = 8 mice per group.
Statistical analysis was performed as indicated in the Methods
section. b Time to tumor size of 100 mm3 was significantly longer for
HUNK shRNA mice relative to control mice based on Kaplan–Meier
survival curve estimates; p = 0.002, log-rank test. Statistical analysis
was performed as indicated in the Methods section







10 10.6 (2.3) 11.6 (3.6) 0.71
17 40.5 (12.0) 30.1 (8.6) 0.93
24 116.3 (16.0) 51.3 (13.5) \0.0001
31 236.4 (57.2) 109.3 (24.4) \0.0001
38 462.4 (57.2) 191.3 (35.9) \0.0001
45 655.4 (67.0) 325.7 (43.6) \0.0001
52 910.3 (92.4) 528.7 (64.4) \0.0001
Analysis includes standard error values and p value at each time
point, n = 8 mice per group at each time point indicated. Statistical
analysis was performed as indicated in the methods section
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increased in the HUNK shRNA cohort (67 days HUNK
shRNA vs. 57.5 days control shRNA, p = 0.005). Addi-
tionally, the median time for HUNK-deficient tumors to
reach a volume of *100 mm3 was significantly delayed
(Fig. 4b, 38 days HUNK shRNA vs. 24 days control
shRNA, p = 0.002).
Despite an obvious delay in tumor initiation, HUNK
shRNA-derived tumors began to grow at a similar rate as
the control tumors, an observation supported by parallel
tumor growth curves when displayed using a semi-log plot
(Supplementary Fig. 1a). Therefore, we analyzed the
resulting tumors that were collected upon completion of
our in vivo analysis to re-examine HUNK expression lev-
els. We found that HUNK levels were similar by QRT-
PCR (Supplementary Fig. 1b) and by immunoblotting
(Supplementary Fig. 1c) in the control and HUNK shRNA
tumor groups, despite the fact that JIMT-1 cells containing
HUNK shRNA were initially knocked down for HUNK
(Fig. 3a). This finding suggests that there is likely a
selective pressure for the HER2 inhibitor-resistant JIMT-1
tumor cells to reject or overcome HUNK knockdown by
shRNA and maintain HUNK expression for survival.
Taken together, our in vivo finding that inhibiting
HUNK in resistant JIMT-1 breast cancer cells impairs
tumor growth is in line with our in vitro findings that
HUNK regulates cell survival and modulates autophagy.
Furthermore, our observation that a selective pressure for
tumor cells to maintain HUNK expression as a means to
promote tumor growth is consistent with our findings that
HUNK promotes tumor cell survival by regulating apop-
tosis and autophagy. As a whole, the observations we
present suggest that targeting HUNK in breast cancers
resistant to HER2-targeted inhibitors has the potential to be
therapeutically beneficial.
Discussion
Although a role for HUNK in promoting breast cancer
initiation [4, 5] and metastasis [2, 3] has been uncovered,
little is known about the intracellular function of this
kinase. Evidence is mounting for a role for HUNK in
regulating cell survival. Previous findings indicate that
HUNK regulates apoptosis [4, 5]. We now report that
HUNK also regulates cell survival via autophagy. This
finding is significant because autophagy is a mechanism by
which breast cancer cells have been shown to survive
treatment and acquire resistance [14, 17, 20]. However, to
some degree, the role of autophagy in human cancer is still
unclear as this process is reported as both tumor promoting
[14, 17, 20–25] and tumor inhibitory [26–28]. This paradox
is exemplified in HER2? breast cancer in which mono-
allelic deletion of the autophagy gene BECN-1 is
frequently found yet these tumors are more sensitive to
HER2-targeted therapy [29]. This suggests that during
early stages of tumor development, autophagy is tumor
inhibitory but once a tumor is fully developed inhibiting
autophagy makes treatment much more effective. Conse-
quently, to clarify how to therapeutically target autophagy
in breast cancer, carefully mapping the cell signaling
pathways and molecules that control these processes is
critical to develop effective breast cancer therapies.
Consistent with the idea that autophagy status influences
tumor cell survival in response to treatment, autophagy
competent tumor cells will adapt by utilizing autophagy to
survive treatment, thus acquiring resistance. Therefore,
being able to simultaneously induce tumor cell death by
apoptosis and impair survival by autophagy has the
potential to allow tumor cells to evade resistance. This
strategy is directly applicable to HER2? breast cancer
because chronic application of HER2 inhibitors (i.e.,
trastuzumab and lapatinib) has been shown to lead to the
up-regulation of autophagy response [14, 17] and survival
signaling pathways, like the PI3K/Akt pathway, in breast
cancer cells to promote cell survival [30]. Our new findings
implicate HUNK as an attractive target because this kinase
not only signals through HER2 [4] and PI3K/Akt [5] but
we now show HUNK also regulates cell survival by
impacting both apoptosis and autophagy.
While intriguing, additional investigation is warranted as
we do not yet know the mechanism by which HUNK reg-
ulates autophagy and how this relates to apoptosis. It is
possible that HUNK regulates these processes individually
or alternatively and mediates crosstalk between the two
pathways. We have previously demonstrated that HUNK
can regulate p27 downstream of HER2 activation and
attribute HUNK’s ability to promote survival, at least in part
due to this function [4]. Interestingly, p27 has been impli-
cated in autophagy, and this function of p27 is directed by
its phosphorylation at Threonine (T) 198 [31]. The phos-
phorylation of p27 on T198 can be directed by multiple
kinases including AMPK [31], Akt [32], and Rsk1 [33].
AMPK-directed phosphorylation of p27 is associated with
p27’s function toward autophagy [31] whereas phosphory-
lation of p27 by Akt mediates cell survival [32]. We have
shown that HUNK is upregulated by Akt [5]. Accordingly,
it is possible that HUNK could have a selective function
toward Akt-specific downstream signaling molecules, and it
will be interesting to determine if HUNK regulates p27 in
an Akt-dependent manner. Furthermore, it is perhaps
appealing to speculate that an overlapping mechanism for
HUNK exists toward Akt-specific substrates such as tran-
scriptional regulation, modulation of protein localization, or
sequestration of proteins in inactive complexes—perhaps
by HUNK-directed phosphorylation. However, very little is
known about the kinase activity of HUNK or its preferred
96 Breast Cancer Res Treat (2015) 149:91–98
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phosphorylation consensus site. Consequently, this line of
investigation is better suited for future studies.
In conclusion, our collective findings to date demon-
strate that HUNK is a critical survival protein in HER2?
breast cancer cells. We have shown that HUNK regulates
tumor cell survival by mediating apoptosis, and now we
have also demonstrated that HUNK regulates survival by
mediating autophagy. Taken together, these findings
implicate HUNK as a potential target in HER2? breast
cancer that has the potential to be therapeutically beneficial
in fighting resistance to HER2-targeted therapies.
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